Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aromasin (IM vs Oral) in Advanced Breast Cancer
NCT00040014Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2002
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Plasma estrone sulphate inhibitory effect at steady state. Started Jun 2002; status: terminated.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00040014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040014.